IMAGE: Cryo-EM reconstructions show how two different antibodies (blue) bind to the spike protein of the SARS-CoV-2 virus.
IMAGE: Cryo-EM reconstructions show how two different antibodies (blue) bind to the spike protein of the SARS-CoV-2 virus.
The results of the Phase I/II trial published in the scientific journal, The Lancet, indicate no early safety concerns and induces strong immune responses in both parts of the immune system.
Drug Controller General of India (DCGI) has given approval to the first fully indigenously developed Pneumococcal Polysaccharide Conjugate Vaccine. This vaccine has been developed by Serum Institute of India, Pune.
Scientists from the Institute of Nano Science & Technology (INST), Mohali, an autonomous institute of the Department of Science and Technology Government of India, have formulated nanoparticles with chitosan and loaded these nanoparticles with zinc gluconate for reducing the severity of rheumatoid arthritis.
TLeishmaniasis is a neglected tropical disease affecting almost 100 countries including India. It is caused by a parasite called Leishmania, which is transmitted through the bite of sand flies.
A novel formulation of the prostate cancer drug abiraterone acetate - currently marketed as Zytiga - will dramatically improve the quality of life for people suffering from prostate cancer, as pre-clinical trials by the University of South Australia show the new formulation improves the drug's effectiveness by 40 per cent.
Caption : A novel formulation of the prostate cancer drug abiraterone acetate - currently marketed as Zytiga - will dramatically improve the quality of life for people suffering from prostate cancer. Credit : Hayley Schultz/UniSA
New research indicates that taking vitamin D supplements may help prevent a potentially serious side effect of a revolutionary form of anti-cancer therapy. The findings are published early online in CANCER, a peer-reviewed journal of the American Cancer Society (ACS).
The Central Drug Research Institute (CDRI), Lucknow, has received permission from Drug Controller General of India (DCGI) for carrying out Phase III clinical trials to test the efficacy, safety and tolerability of the antiviral drug Umifenovir. The Phase III activities will be carried out at King George's Medical University (KGMU), Dr Ram Manohar Lohia Institute of Medical Sciences (RMLIMS) and ERA's Lucknow Medical College and Hospital, Lucknow.